早期治疗后PET/CT评估FDG或18F-FCH预测肝细胞癌90Y放射栓塞疗效
回顾性研究纳入37例接受TARE的HCC患者,治疗后4-8周行FDG和/或18F-FCH PET/CT。早期PET/CT响应预测6个月mRECIST响应的敏感度和特异度均为100%,且为总生存的独立预测因素。
要点
- 早期PET/CT响应可100%预测6个月mRECIST响应,优于1个月mRECIST。
- FDG或18F-FCH PET/CT响应是OS的独立预测因素(多因素HR 0.2)。
- 早期PET/CT有助于识别TARE真正无响应者,指导早期治疗调整。
关键影像表现/征象
- 治疗前FDG阳性28例(76%),FCH阳性15例(41%),双阳性6例(16%)。
- FDG阳性者中12例早期FDG PET/CT显示响应,FCH阳性者中7例早期FCH PET/CT显示响应。
诊断标准与关键数值
- FDG阳性定义为视觉摄取且肿瘤/正常肝比值>1.15。
- 早期PET/CT响应预测6个月mRECIST响应:敏感度100%(12/12),特异度100%(11/11)。
- 1个月mRECIST响应预测6个月mRECIST响应:敏感度67%(8/12),特异度100%(11/11)。
临床应用与阅片要点
- TARE后4-8周行FDG或18F-FCH PET/CT可早期识别无响应者。
- FDG阴性HCC可借助18F-FCH PET/CT评估。
- 早期PET/CT响应或可替代1个月mRECIST用于早期疗效判断。
局限性
- 回顾性单中心研究,样本量较小(37例)。
- 仅23例完成1个月和6个月mRECIST评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Assessment of hepatocellular carcinoma (HCC) treatment response after transarterial radioembolization (TARE) is challenging, because response by conventional imaging criteria may not become apparent until 6 months after treatment. Though HCC exhibits variable avidity for FDG, some cases of HCC without avidity for FDG show avidity for 18F-fluorocholine (18F-FCH). OBJECTIVE. The purpose of this study was to evaluate the utility of early posttreatment evaluation by PET/CT using FDG or 18F-FCH to predict 6-month treatment response and survival after TARE in patients with HCC. METHODS. This retrospective study included 37 patients (mean age, 67 years; 34 men, three women) with documented HCC treated by TARE who underwent both pre-treatment FDG PET/CT and 18F-FCH PET/CT and early FDG PET/CT and/or 18F-FCH PET/CT 4-8 weeks after treatment; FDG PET/CT and 18F-FCH PET/CT examinations were performed on separate dates. Only one of 73 initially identified potentially eligible patients was excluded because of lack of HCC avidity for both FDG and 18F-FCH. Response assessment by modified RECIST (mRECIST) on multiphase CT or MRI was performed at 1 month and 6 months in 23 patients. Early responses seen on PET/CT and 1-month mRECIST response were assessed as predictors of 6-month mRECIST response. Univariable and multivariable predictors of overall survival (OS) were identified. RESULTS. On pretreatment PET/CT, 28 (76%) patients were FDG-positive (showed visual uptake on FDG PET/CT and tumor-to-normal liver ratio > 1.15), 15 (41%) were FCH-positive (showed visual uptake on 18F-FCH PET/CT), and six (16%) were both FDG-positive and FCH-positive. Twelve of 28 FDG-positive HCCs exhibited early response by FDG PET/CT; seven of 15 FCH-positive HCCs exhibited early response by 18F-FCH PET/CT. Twelve (52%) patients exhibited 6-month mRECIST response. Response seen on early posttreatment PET/CT exhibited 100% (12/12) sensitivity and 100% (11/11) specificity for 6-month mRECIST response, whereas 1-month mRECIST response exhibited 67% (8/12) sensitivity and 100% (11/11) specificity for 6-month mRECIST response. Response seen on early posttreatment PET/CT was a significant independent predictor of OS on univariable (hazard ratio [HR], 0.4; 95% CI, 0.2-0.9; p = .03) and multivariable (HR, 0.2; 95% CI, 0.1-0.8; p = .01) analyses. CONCLUSION. Early evaluation after TARE by PET/CT using FDG or 18F-FCH may pre dict 6-month response and OS in patients with HCC. CLINICAL IMPACT. Early posttreatment evaluation with PET/CT could help more reliably identify true nonresponders after TARE, which in turn could prompt early response-adapted therapeutic management.
引用
- Reizine E, Chalaye J, Mule S, et al. Utility of Early Posttreatment PET/CT Evaluation Using FDG or 18F-FCH to Predict Response to 90Y Radioembolization in Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol. 2021. PMID: 34494448. doi:10.2214/AJR.21.26485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。